NCT05214599View on ClinicalTrials.gov

Pharmacokinetics, Efficacy, Tolerability and Safety of Different Budesonide Oral Gel Doses in Adults' Subjects of Both Genders With Eosinophilic Esophagitis (EoE)

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

April 23, 2021

Primary Completion Date

November 30, 2024

Study Completion Date

April 30, 2025

Conditions
Eosinophilic Esophagitis
Interventions
DRUG

Budesonide Gel

Twice daily regimen

Sponsors

Lead Sponsor

Bazell Pharma AG
All Listed Sponsors
lead

Bazell Pharma AG

INDUSTRY